Advertisement

Topics

[Comment] Maintaining quality of life for patients with neuroendocrine tumours

01:03 EDT 22 Aug 2017 | The Lancet

Ideally, new treatments should either improve overall survival or the health-related quality of life (HRQOL) of patients, or both, and should have a favourable cost-to-benefit ratio. For instance, FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) significantly improves progression-free survival, overall survival, and HRQOL compared with gemcitabine in patients with metastatic pancreatic adenocarcinoma, even though it causes substantially more side-effects.1,2 After publication of the RADIANT-3 and RADIANT-4 randomised, placebo-controlled, phase 3 studies, everolimus was approved for all non-functional, advanced, neuroendocrine tumours (NETs), including those of the pancreas,3 lung, and gastrointestinal tract,4 and sunitinib has been approved for pancreatic NETs (pNETs).

Original Article: [Comment] Maintaining quality of life for patients with neuroendocrine tumours

NEXT ARTICLE

More From BioPortfolio on "[Comment] Maintaining quality of life for patients with neuroendocrine tumours"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...